$GRTSQ
Gritstone bio, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021002819 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $3.064M $2.614M $939.0K
YoY Change 127.3% 178.38% -4.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.682M $6.373M $5.030M
YoY Change 18.06% 26.7% 9.83%
% of Gross Profit
Research & Development $26.17M $24.40M $22.05M
YoY Change 14.56% 10.64% -11.4%
% of Gross Profit
Depreciation & Amortization $1.565M $1.589M $1.670M
YoY Change -7.4% -4.85% 42.74%
% of Gross Profit
Operating Expenses $32.85M $30.77M $27.08M
YoY Change 15.26% 13.62% -8.1%
Operating Profit -$28.16M -$26.14M
YoY Change 7.7% -8.22%
Interest Expense $15.00K $37.00K $69.00K
YoY Change -175.0% -46.38% -92.63%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$29.77M -$28.12M -$26.07M
YoY Change 9.57% 7.86% -5.37%
Income Tax
% Of Pretax Income
Net Earnings -$29.77M -$28.12M -$26.07M
YoY Change 9.58% 7.84% -5.35%
Net Earnings / Revenue -971.57% -1075.67% -2776.68%
Basic Earnings Per Share -$0.36
Diluted Earnings Per Share -$377.4K -$361.5K -$690.6K
COMMON SHARES
Basic Shares Outstanding 67.99M 77.78M 37.75M
Diluted Shares Outstanding 77.78M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.3M $199.7M $70.50M
YoY Change 20.57% 183.23% -52.84%
Cash & Equivalents $93.29M $131.4M $57.65M
Short-Term Investments $113.0M $68.26M $12.90M
Other Short-Term Assets $866.0K $814.0K $403.0K
YoY Change 223.13% 101.99% -50.06%
Inventory
Prepaid Expenses
Receivables $1.385M $1.096M
Other Receivables $0.00 $0.00
Total Short-Term Assets $220.6M $218.4M $73.70M
YoY Change 25.77% 196.34% -52.39%
LONG-TERM ASSETS
Property, Plant & Equipment $21.62M $21.34M $23.31M
YoY Change -2.19% -8.45% -52.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.617M
YoY Change
Other Assets $8.357M $7.751M $2.700M
YoY Change 209.52% 187.07% 0.0%
Total Long-Term Assets $57.52M $52.88M $48.80M
YoY Change 24.56% 8.36% -9.46%
TOTAL ASSETS
Total Short-Term Assets $220.6M $218.4M $73.70M
Total Long-Term Assets $57.52M $52.88M $48.80M
Total Assets $278.1M $271.3M $122.5M
YoY Change 25.52% 121.45% -41.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.230M $3.393M $3.300M
YoY Change -55.84% 2.82% -50.75%
Accrued Expenses $411.0K $3.022M $13.20M
YoY Change -39.29% -77.11% 22.22%
Deferred Revenue $17.20M $13.79M
YoY Change 394.99%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.96M $36.31M $22.00M
YoY Change 48.05% 65.06% -3.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $395.0K $28.50M
YoY Change -100.0% -98.61% -3.06%
Total Long-Term Liabilities $0.00 $395.0K $28.50M
YoY Change -100.0% -98.61% -3.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.96M $36.31M $22.00M
Total Long-Term Liabilities $0.00 $395.0K $28.50M
Total Liabilities $62.02M $63.33M $50.50M
YoY Change 13.12% 25.4% -3.44%
SHAREHOLDERS EQUITY
Retained Earnings -$401.4M -$371.6M -$299.1M
YoY Change 23.02% 24.24%
Common Stock $20.00K $20.00K
YoY Change 11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $216.1M $208.0M $71.98M
YoY Change
Total Liabilities & Shareholders Equity $278.1M $271.3M $122.5M
YoY Change 25.52% 121.45% -41.3%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$29.77M -$28.12M -$26.07M
YoY Change 9.58% 7.84% -5.35%
Depreciation, Depletion And Amortization $1.565M $1.589M $1.670M
YoY Change -7.4% -4.85% 42.74%
Cash From Operating Activities -$23.78M -$14.87M -$20.18M
YoY Change -5.68% -26.31% -19.34%
INVESTING ACTIVITIES
Capital Expenditures -$1.330M -$1.473M -$610.0K
YoY Change 375.0% 141.48% -89.39%
Acquisitions
YoY Change
Other Investing Activities -$45.30M $42.63M $16.35M
YoY Change -480.96% 160.75% -58.85%
Cash From Investing Activities -$46.63M $41.16M $15.73M
YoY Change -501.26% 161.67% -53.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.88M 56.74M 40.00K
YoY Change -73.79% 141757.5% -84.0%
NET CHANGE
Cash From Operating Activities -23.78M -14.87M -20.18M
Cash From Investing Activities -46.63M 41.16M 15.73M
Cash From Financing Activities 32.88M 56.74M 40.00K
Net Change In Cash -37.53M 83.03M -4.410M
YoY Change -133.56% -1982.81% -147.88%
FREE CASH FLOW
Cash From Operating Activities -$23.78M -$14.87M -$20.18M
Capital Expenditures -$1.330M -$1.473M -$610.0K
Free Cash Flow -$22.45M -$13.40M -$19.57M
YoY Change -9.95% -31.54% 1.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001656634
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38663
dei Entity Registrant Name
EntityRegistrantName
Gritstone bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4859534
dei Entity Address Address Line1
EntityAddressAddressLine1
5959 Horton Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
871-6100
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
GRTS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67987825
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131423000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170056000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
68255000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1002000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
10995000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7728000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4332000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
218401000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
175390000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5687000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21337000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22105000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23793000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21344000
CY2021Q3 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2064000
CY2020Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
1736000
CY2021Q3 us-gaap Assets
Assets
271282000
CY2020Q4 us-gaap Assets
Assets
221567000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3393000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9578000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6115000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6331000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3022000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
677000
CY2021Q3 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2540000
CY2020Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1053000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7458000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5874000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13786000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3475000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36314000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26988000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
395000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
395000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19844000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19225000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6774000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8220000
CY2021Q3 us-gaap Liabilities
Liabilities
63327000
CY2020Q4 us-gaap Liabilities
Liabilities
54828000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64251581
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64251581
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47552693
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47552693
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
20000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
579543000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
493023000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371615000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326302000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
207955000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166739000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
271282000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221567000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2614000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
939000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45150000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2688000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24396000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22050000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71324000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65807000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6373000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5031000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19251000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15751000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
30769000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
27081000
us-gaap Operating Expenses
OperatingExpenses
90575000
us-gaap Operating Expenses
OperatingExpenses
81558000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28155000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26142000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45425000
us-gaap Operating Income Loss
OperatingIncomeLoss
-78870000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
69000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
112000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
723000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28118000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26073000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
us-gaap Net Income Loss
NetIncomeLoss
-78147000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-7000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-45000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-19000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28125000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26118000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45306000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78166000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77775497
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37750145
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76837503
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37268318
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
178825000
CY2021Q3 grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
40000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-7000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1062000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2819000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28118000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
207955000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
96228000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-45000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1837000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26073000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
71984000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166739000
grts Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants
AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
-451000
grts Stock Issued During Period Value Purchase Agreement
StockIssuedDuringPeriodValuePurchaseAgreement
20830000
grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
40000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
279000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3108000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7753000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
207955000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
134344000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
527000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-19000
grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
11000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5415000
us-gaap Net Income Loss
NetIncomeLoss
-78147000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
71984000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
us-gaap Net Income Loss
NetIncomeLoss
-78147000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4782000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4951000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-549000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
123000
us-gaap Share Based Compensation
ShareBasedCompensation
7753000
us-gaap Share Based Compensation
ShareBasedCompensation
5415000
us-gaap Operating Lease Cost
OperatingLeaseCost
5743000
us-gaap Operating Lease Cost
OperatingLeaseCost
5621000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3484000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-853000
grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
327000
grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
-29000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-942000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-200000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-216000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
311000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
106000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
1041000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1487000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
778000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-5902000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-2512000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8865000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1902000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26899000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63885000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
133409000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8809000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
59390000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
60982000
grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
6225000
grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
5401000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4133000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3243000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71927000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
54331000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
6026000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
104000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75883000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10369000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22943000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
815000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171048000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58400000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148105000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59215000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
96000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
2313000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
6562000
grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
3174000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28100000
us-gaap Net Income Loss
NetIncomeLoss
-45300000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26100000
us-gaap Net Income Loss
NetIncomeLoss
-78100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63900000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371600000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326300000
CY2021Q3 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
199700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to preclinical and clinical study trial accruals, fair value of assets and liabilities, the fair value of right-of-use assets (“ROU Assets”) and lease liabilities, fair value of pre-funded warrants, revenue recognition, and the fair value of stock-based compensation awards. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the condensed consolidated balance sheets. As of September 30, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131423000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170056000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
16682000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
992000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
148105000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
171048000
CY2020Q4 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q4 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
37803000
grts Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
no material realized gains or losses
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 grts Use Of Net Operating Losses Suspension Period For Medium And Large Business
UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness
P3Y
CY2020Q2 grts Use Of Business Incentive Tax Credits Period Cap
UseOfBusinessIncentiveTaxCreditsPeriodCap
P3Y
CY2021Q3 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
134703000
CY2021Q3 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2021Q3 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2021Q3 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
134710000
CY2020Q4 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
37803000
CY2020Q4 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
41510000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38964000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21693000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16925000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21337000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22105000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4800000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000000.0
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1922000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1906000
us-gaap Operating Lease Cost
OperatingLeaseCost
5743000
us-gaap Operating Lease Cost
OperatingLeaseCost
5621000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1922000
CY2020Q3 us-gaap Lease Cost
LeaseCost
1906000
us-gaap Lease Cost
LeaseCost
5743000
us-gaap Lease Cost
LeaseCost
5629000
us-gaap Operating Lease Payments
OperatingLeasePayments
5902000
us-gaap Operating Lease Payments
OperatingLeasePayments
3446000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6562000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3174000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6M3D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.073
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2024000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8800000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9834000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12436000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10504000
CY2021Q3 grts Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
69777000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
113375000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6960000
CY2021Q3 grts Operating Lease Payment Under The Boston Lease
OperatingLeasePaymentUnderTheBostonLease
79113000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27302000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7458000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19844000
CY2021Q3 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
3480000
CY2020Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
2584000
CY2021Q3 grts Net Contract Asset
NetContractAsset
1096000
CY2020Q4 grts Net Contract Asset
NetContractAsset
0
CY2021Q3 grts Collaboration Receivable
CollaborationReceivable
2132000
CY2020Q4 grts Collaboration Receivable
CollaborationReceivable
0
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
10000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1480000
CY2021Q3 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
196000
CY2020Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
8000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
814000
grts Warrants Outstanding
WarrantsOutstanding
0
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
260000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7728000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4332000
CY2021Q3 us-gaap Security Deposit
SecurityDeposit
1543000
CY2020Q4 us-gaap Security Deposit
SecurityDeposit
1218000
CY2021Q3 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
521000
CY2020Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
518000
CY2021Q3 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2064000
CY2020Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
1736000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1169591
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64251581
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64251581
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47552693
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47552693
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote per share.
CY2019Q4 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000.0
CY2019Q4 grts Percentage Of Proceeds Payable As Compensation To Underwriter
PercentageOfProceedsPayableAsCompensationToUnderwriter
0.030
CY2019Q4 grts Maximum Offering Expenses Agreed To Be Reimbursed
MaximumOfferingExpensesAgreedToBeReimbursed
50000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
87700000
grts Class Of Warrant Or Right Issue Date
ClassOfWarrantOrRightIssueDate
2020-12-28
grts Class Of Warrant Or Rights Expiration
ClassOfWarrantOrRightsExpiration
None
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.34
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17919971
CY2021Q3 grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
9560748
grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
9560748
grts Warrants Issued
WarrantsIssued
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3108412
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4166441
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.13
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2092000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2692507
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2165450
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2165450
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.93
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
638692
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
411865
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
411865
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.47
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4047334
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5281334
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10349000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2112050
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6343000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4847632
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M26D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9810000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
880600
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
103600
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
5.29
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
777000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.29
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2819000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1837000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7753000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5415000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28118000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26073000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
us-gaap Net Income Loss
NetIncomeLoss
-78147000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77775497
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37750145
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76837503
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37268318
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
CY2021Q3 grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
9560748
grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
9560748
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5281474
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4624285

Files In Submission

Name View Source Status
0000950170-21-002819-index-headers.html Edgar Link pending
0000950170-21-002819-index.html Edgar Link pending
0000950170-21-002819.txt Edgar Link pending
0000950170-21-002819-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grts-20210930.htm Edgar Link pending
grts-20210930.xsd Edgar Link pending
grts-20210930_cal.xml Edgar Link unprocessable
grts-20210930_def.xml Edgar Link unprocessable
grts-20210930_htm.xml Edgar Link completed
grts-20210930_lab.xml Edgar Link unprocessable
grts-20210930_pre.xml Edgar Link unprocessable
grts-ex31_1.htm Edgar Link pending
grts-ex31_2.htm Edgar Link pending
grts-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending